WEKO3
アイテム
{"_buckets": {"deposit": "cd4eb7b4-d72c-4bc5-8dd5-2df9e9c2de37"}, "_deposit": {"created_by": 2, "id": "264", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "264"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00000264", "sets": ["11"]}, "author_link": ["1329", "1343", "1340", "1333", "1327", "1338", "1345", "1342", "1339", "1331", "1336", "1335", "1332", "1328", "1348", "1341", "1334", "1346", "1347", "1337", "1330", "1344"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-07-31", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "216", "bibliographicPageStart": "209", "bibliographicVolumeNumber": "248", "bibliographic_titles": [{"bibliographic_title": "The Tohoku Journal of Experimental Medicine"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic joint inflammation and may manifest as interstitial pneumonia (IP). Methotrexate (MTX) is one of the main therapeutic drugs used for RA, but MTX could cause severe side effects, including Pneumocystis jirovecii pneumonia (PCP) and IP. Owing to similar symptoms, it is sometimes difficult to discriminate MTX therapy-associated PCP (MTX-PCP) and MTX therapy-associated IP (MTX-IP). Soluble interleukin-2 receptor (sIL-2R) is considered a marker of T-cell activation, and serum sIL-2R levels are elevated in RA and PCP. This led us to hypothesize that serum sIL-2R is a potential biomarker for discriminating MTX-PCP and MTX-IP. Accordingly, we carried out a retrospective analysis of 20 MITX-PCP cases, 30 MTX-IP cases, and as controls, 16 patients with RA-associated IP (RA-IP) and 13 patients with PCP without MTX treatment (PCP group). C-reactive protein and alveolar-arterial oxygen differences were higher in the MTX-PCP group than those in the RA-IP and MTX-IP groups. Importantly, serum levels of sIL-2R in MTX-PCP were significantly higher than those in other three groups. Based on the receiver operating characteristic curve, the cut-off level of sIL-2R resulting in the highest diagnostic accuracy for MTX-PCP was 1,311.5 U/mL, discriminating between MTX-PCP and other groups with 91.7% sensitivity and 78.6% specificity. Thus, patients with MTX-PCP show a higher degree of systemic inflammation, severe hypoxemia, and increased sIL-2R levels compared with those in MTX-IP cases. In conclusion, serum sIL-2R could be a biomarker for PCP diagnosis among patients with RA under MTX therapy.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Tohoku Journal of Experimental Medicine, 248(3), pp.209-216; 2019", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Tohoku University Medical Press"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1620/tjem.248.209", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2019 Tohoku University Medical Press."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00408727", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "13493329", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sakamoto, Noriho"}], "nameIdentifiers": [{"nameIdentifier": "1327", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hara, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "1328", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishimoto, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "1329", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakashima, Shota"}], "nameIdentifiers": [{"nameIdentifier": "1330", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yura, Hirokazu"}], "nameIdentifiers": [{"nameIdentifier": "1331", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyamura, Takuto"}], "nameIdentifiers": [{"nameIdentifier": "1332", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuno, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "1333", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hara, Atsuko"}], "nameIdentifiers": [{"nameIdentifier": "1334", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kakugawa, Tomoyuki"}], "nameIdentifiers": [{"nameIdentifier": "1335", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "1336", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Obase, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "1337", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kushima, Hisako"}], "nameIdentifiers": [{"nameIdentifier": "1338", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishii, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "1339", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Noguchi, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "1340", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kido, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "1341", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi, Tsutomu"}], "nameIdentifiers": [{"nameIdentifier": "1342", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soejima, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "1343", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshioka, Sumako"}], "nameIdentifiers": [{"nameIdentifier": "1344", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishimatsu, Yuji"}], "nameIdentifiers": [{"nameIdentifier": "1345", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yatera, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "1346", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kadota, Jun-ichi"}], "nameIdentifiers": [{"nameIdentifier": "1347", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "1348", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "TJEM48_209.pdf", "filesize": [{"value": "612.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 612400.0, "url": {"label": "TJEM48_209.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/264/files/TJEM48_209.pdf"}, "version_id": "eb9e5861-fc36-4efa-878d-56e1a4af5f95"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Drug-induced pneumonia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Interleukin-2 receptor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Methotrexate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pneumocystis jirovecii pneumonia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rheumatoid arthritis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/39425", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-08-30"}, "publish_date": "2019-08-30", "publish_status": "0", "recid": "264", "relation": {}, "relation_version_is_last": true, "title": ["Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy"], "weko_shared_id": -1}
Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy
http://hdl.handle.net/10069/39425
http://hdl.handle.net/10069/3942591c266ef-0ebb-4897-a456-b3a47c6ea9ec
名前 / ファイル | ライセンス | アクション |
---|---|---|
TJEM48_209.pdf (612.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-08-30 | |||||
タイトル | ||||||
タイトル | Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Drug-induced pneumonia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Interleukin-2 receptor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Methotrexate | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pneumocystis jirovecii pneumonia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rheumatoid arthritis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Sakamoto, Noriho
× Sakamoto, Noriho× Hara, Shintaro× Ishimoto, Hiroshi× Nakashima, Shota× Yura, Hirokazu× Miyamura, Takuto× Okuno, Daisuke× Hara, Atsuko× Kakugawa, Tomoyuki× Yamaguchi, Hiroyuki× Obase, Yasushi× Kushima, Hisako× Ishii, Hiroshi× Noguchi, Shingo× Kido, Takashi× Kobayashi, Tsutomu× Soejima, Yoshifumi× Yoshioka, Sumako× Ishimatsu, Yuji× Yatera, Kazuhiro× Kadota, Jun-ichi× Mukae, Hiroshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic joint inflammation and may manifest as interstitial pneumonia (IP). Methotrexate (MTX) is one of the main therapeutic drugs used for RA, but MTX could cause severe side effects, including Pneumocystis jirovecii pneumonia (PCP) and IP. Owing to similar symptoms, it is sometimes difficult to discriminate MTX therapy-associated PCP (MTX-PCP) and MTX therapy-associated IP (MTX-IP). Soluble interleukin-2 receptor (sIL-2R) is considered a marker of T-cell activation, and serum sIL-2R levels are elevated in RA and PCP. This led us to hypothesize that serum sIL-2R is a potential biomarker for discriminating MTX-PCP and MTX-IP. Accordingly, we carried out a retrospective analysis of 20 MITX-PCP cases, 30 MTX-IP cases, and as controls, 16 patients with RA-associated IP (RA-IP) and 13 patients with PCP without MTX treatment (PCP group). C-reactive protein and alveolar-arterial oxygen differences were higher in the MTX-PCP group than those in the RA-IP and MTX-IP groups. Importantly, serum levels of sIL-2R in MTX-PCP were significantly higher than those in other three groups. Based on the receiver operating characteristic curve, the cut-off level of sIL-2R resulting in the highest diagnostic accuracy for MTX-PCP was 1,311.5 U/mL, discriminating between MTX-PCP and other groups with 91.7% sensitivity and 78.6% specificity. Thus, patients with MTX-PCP show a higher degree of systemic inflammation, severe hypoxemia, and increased sIL-2R levels compared with those in MTX-IP cases. In conclusion, serum sIL-2R could be a biomarker for PCP diagnosis among patients with RA under MTX therapy. | |||||
書誌情報 |
The Tohoku Journal of Experimental Medicine 巻 248, 号 3, p. 209-216, 発行日 2019-07-31 |
|||||
出版者 | ||||||
出版者 | Tohoku University Medical Press | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00408727 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 13493329 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1620/tjem.248.209 | |||||
権利 | ||||||
権利情報 | c 2019 Tohoku University Medical Press. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Tohoku Journal of Experimental Medicine, 248(3), pp.209-216; 2019 |